Role of Endogenous Endothelin in Chronic Heart Failure

1997361 citationsJournal Article

Authors

Paul Mulder · Université de Rouen Normandie

Vincent Richard · Université de Rouen Normandie

Geneviève Dérumeaux · Université de Rouen Normandie

Manuela Hogie · Université de Rouen Normandie

Jean Paul Henry · Université de Rouen Normandie

Françoise Lallemand · Université de Rouen Normandie

Patricia Compagnon

Abstract

Long-term treatment with an ET antagonist markedly increases survival in this rat model of CHF. This increase in survival is associated with decreases in both preload and afterload and an increase in cardiac output as well as decreased LV hypertrophy, LV dilatation, and cardiac fibrosis. Thus, chronic treatment with ET antagonists such as bosentan might be beneficial in human CHF and might increase long-term survival in this disease.

Topics & Keywords

Nitric Oxide and Endothelin Effects Pulmonary Hypertension Research and Treatments Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 96, Issue 6, pp. 1976-1982

DOI: 10.1161/01.cir.96.6.1976

Field-Weighted Citation Impact: 16.10